Compare SAMG & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SAMG | ELOX |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 60.3M |
| IPO Year | 2012 | 2013 |
| Metric | SAMG | ELOX |
|---|---|---|
| Price | $10.25 | $13.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | ★ 101.6K | 18.6K |
| Earning Date | 10-29-2026 | 08-12-2026 |
| Dividend Yield | ★ 8.24% | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.04 | N/A |
| P/E Ratio | $203.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.09 | $10.00 |
| 52 Week High | $16.16 | $23.40 |
| Indicator | SAMG | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 36.73 |
| Support Level | $9.69 | $10.74 |
| Resistance Level | $10.63 | $14.65 |
| Average True Range (ATR) | 0.40 | 1.35 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 67.84 | 8.05 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.